Taken, together these data suggest SLC22A16 can transport 14C-doxorubicin in DLBCL cells and that loss of SLC22A16 through gene deletion or mutation could impact the sensitivity of DLBCL cells toward doxorubicin-containing therapies. The gene discussed is SLC22A16; the disease is diffuse large B-cell lymphoma.